TY - JOUR
T1 - Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis
T2 - Correlation with interstitial lung disease
AU - Ihn, H.
AU - Asano, Y.
AU - Kubo, M.
AU - Yamane, K.
AU - Jinnin, M.
AU - Yazawa, N.
AU - Fujimoto, M.
AU - Tamaki, K.
N1 - Funding Information:
This study was supported in part by a grant for scientific research from the Japanese Ministry of Education (10770391) and by project research for progressive systemic sclerosis from the Japanese Ministry of Health and Welfare.
PY - 2002/11/1
Y1 - 2002/11/1
N2 - Objective. To determine the clinical significance of serum surfactant protein D (SP-D) levels in patients with polymyositis/dermatomyositis (PM/DM). Methods. Serum SP-D levels were assayed using a sensitive enzyme-linked immunosorbent assay in 59 patients with PM/DM and in 29 healthy controls. Results. The serum level of SP-D was significantly higher in patients with PM/DM than in healthy controls (mean ± S.D. 61.7 ± 122.6 vs 31.0 ± 12.4 ng/ml, P < 0.01). The serum SP-D level in patients with interstitial lung disease (ILD) was significantly higher than in those without ILD (118.7 ± 220.2 vs 38.7 ± 21.0 ng/ml, P < 0.001). Serum level of SP-D was correlated with the presence of ILD. The incidences of decreased vital capacity (%VC) and of decreased diffusing capacity of carbon monoxidase (%DLCO) were also significantly greater in patients with an elevated SP-D level than in those with a normal level (64 vs 7%, P < 0.02; 73 vs 27%, P < 0.01). Moreover, the serum SP-D level was inversely correlated with %VC (r 0.452, P < 0.01) and %DLCO (r= -0.349, P < 0.05). Conclusion. The serum SP-D level may be a useful marker for ILD in patients with PM/DM.
AB - Objective. To determine the clinical significance of serum surfactant protein D (SP-D) levels in patients with polymyositis/dermatomyositis (PM/DM). Methods. Serum SP-D levels were assayed using a sensitive enzyme-linked immunosorbent assay in 59 patients with PM/DM and in 29 healthy controls. Results. The serum level of SP-D was significantly higher in patients with PM/DM than in healthy controls (mean ± S.D. 61.7 ± 122.6 vs 31.0 ± 12.4 ng/ml, P < 0.01). The serum SP-D level in patients with interstitial lung disease (ILD) was significantly higher than in those without ILD (118.7 ± 220.2 vs 38.7 ± 21.0 ng/ml, P < 0.001). Serum level of SP-D was correlated with the presence of ILD. The incidences of decreased vital capacity (%VC) and of decreased diffusing capacity of carbon monoxidase (%DLCO) were also significantly greater in patients with an elevated SP-D level than in those with a normal level (64 vs 7%, P < 0.02; 73 vs 27%, P < 0.01). Moreover, the serum SP-D level was inversely correlated with %VC (r 0.452, P < 0.01) and %DLCO (r= -0.349, P < 0.05). Conclusion. The serum SP-D level may be a useful marker for ILD in patients with PM/DM.
KW - Enzyme-linked immunosorbent assay
KW - Interstitial lung disease
KW - Vital capacity
UR - http://www.scopus.com/inward/record.url?scp=0036851420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036851420&partnerID=8YFLogxK
M3 - Article
C2 - 12421999
AN - SCOPUS:0036851420
SN - 1462-0324
VL - 41
SP - 1268
EP - 1272
JO - Rheumatology and Rehabilitation
JF - Rheumatology and Rehabilitation
IS - 11
ER -